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The efficacy of continuous and intermittent nitroglycerin 
patches (10 mg/day) was compared in a randomized, pla- 
cebo-controlled trial in 36 patients with stable angina and 
reproducible, exercise-induced ST depression. Intermittent 
treatment was administered either 18 or 14 h/day with an 
intermission of 6 h or 10 h, respectively. Exercise tests were 
performed during the last 2 h of patch application. Com- 
pared with placebo, neither continuous nitroglycerin nor 
the two intermittent regimens prolonged total treadmill 
time or time to 1 mm ST depression. No treatment elimi- 
nated exercise-induced ST depression in >l of the 36 
patients. Time to angina was prolonged (by 40 f 66 s) only 
during the “10 h off’ treatment (p = 0.001); time to angina 
increased by ~20% in 13 patients. 
Responders to treatment could be predicted by a short 
history of angina (p < 0.05) and a time to angina 5250 s 
during the placebo test. For each treatment, ~25 of the 
patients reported headache; 4 additional patients dropped 
out because of severe headache and 2 others because of a 
coronary event in a washout period. Thus, in most patients 
with stable angina, side effects outweigh any benefit demon- 
strable with this therapy. 
(J Am Co11 Cardiol 1989;13:421-5) 
Transdermal patches to administer nitroglycerin are widely 
used in the treatment of angina. These systems can maintain 
constant serum nitroglycerin levels over 24 h (I) and in most 
(2-12) but not all (13.14) controlled studies, antianginal 
efficacy can be demonstrated during the first 8 h after 
application. However, efficacy may not persist for 24 h (2-5) 
and tolerance develops soon after the start of treatment, so 
that by I week even early post-dose efficacy may be lost 
(2.11,12). 
Nitrate-free intervals have been proposed as the solution 
to the problem of tolerance. In three studies (10-12) where 
the patches were removed overnight for 8 or 10 h, persistent 
efficacy during long-term therapy could be demonstrated 2 to 
8 h after patch application. This study was undertaken to 
extend these observations. We compared the continuous 
administration of nitroglycerin with two intermittent trans- 
dermal nitroglycerin regimens: one with active patch for I8 
h/day (6 h “off”) and the other with active patch for 14 h/day 
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E.ucllrded ftwn the study were patients with myocardial 
infarction, unstable angina or coronary bypass surgery 
within 3 months, overt cardiac failure, severe hypertension, 
significant arrhythmias or baseline ECG abnormalities that 
interfere with the interpretation of ST segment changes 
during exercise. Six of the 42 patients did not complete the 
study: 4 developed severe headache during their first periods 
with active treatment. and 2 experienced a coronary event 
01989 by the American College ol’ Cardiology 0715-1097:8Y/%3.50 
(10 h “off’). Efficacy was assessed by treadmill exercise 
testing during the last 2 h of patch application. 
Methods 
Patient selection. A total of 42 patients with chronic 
stable angina were enrolled in the trial. All had documented 
coronary artery disease defined as I) coronary stenosis 
~70% of luminal diameter at arteriography; 2) previous 
transmural myocardial infarction with elevated cardiac 
isoenzymes and electrocardiographic (ECG) Minnesota code 
criteria (15); or 3) a reversible perfusion deficit on thallium 
exercise testing. All patients had both angina and 2 1 mm of 
ST segment depression compared with baseline during stan- 
dard treadmill exercise testing with the Bruce protocol. 
Exercise reproducibility was confirmed by two baseline tests 
that demonstrated ~20% variability in exercise time to 1 mm 
ST segment depression. 
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Table 1. Summary of the Three Treatment Regimens in 
36 Patients 
Sequence 
Continuous 
6 h off 
10 h off 
Active 
Patch Worn 
10PM tO4PM 
t0 10 PM 
ioPMtO4PM 
10 PM to noon 
Exercise Test: 
Time of Day 
2 PM t0 4 PM 
2 PM t0 4 PM 
10 AM t0 noon 
Hours From 
Patch Application 
to Exercise Test 
16 to 18 
16 to 18 
12 to 14 
(myocardial infarction in 1 and unstable angina in 1) during a 
washout period after active treatment. 
The mean age of the 36 patients who completed the trial 
was 60 +- 8 years (range 40 to 70); 29 were men and 7 were 
women. The mean duration of angina was 5 -+ 5 years (range 
3 months to 20 years). Mild hypertension was present in 10, 
previous infarction in 12 and prior bypass surgery in 10; 5 
patients were current smokers and 26 took a stable dose of a 
beta-adrenergic blocking drug during the study. With the 
exception of sublingual nitroglycerin, other antianginal drugs 
were not permitted. New York Heart Association functional 
class was I in 7, II in 23 and III in 6 patients. 
Study protocol. The study was a single blind, three treat- 
ment crossover comparison with patients equally random- 
ized to each treatment sequence. The three treatment regi- 
mens (Table 1) consisted of 1) transdermal nitroglycerin 
administered continuously over 24 h; 2) transdermal nitro- 
glycerin administered for 18 h/day with 6 h “off ‘; and 3) 
transdermal nitroglycerin administered for 14 h/day with 10 h 
,‘Off.” 
The continuous nitroglycerin sequence consisted of two 
patches, worn from 10 PM to 4 PM andfrom 4 PM to 10 PM. 
For the “6 h off’ regimen, an active patch was worn from 10 
PM to 4 PM and a placebo patch from 4 PM to 10 PM. For the 
“10 h off’ regimen, the active patch was worn from 10 PM to 
noon and a placebo patch from noon to 10 PM. 
Active patches were 20 cm2 and contained 50 mg of 
nitroglycerin (Ciba-Geigy) released at approximately 0.5 mg/ 
cm*/24 h (10 mg124 h) (1). Placebo patches were identical to 
the active systems but contained no drug. Patches were 
applied to a clean, dry, hairless area of skin, most commonly 
on the lower chest. A fresh site was used for each new patch. 
The duration of the study was 4 weeks, with the 1st week 
used to establish the reproducibility of the baseline exercise 
test. In each of the other 3 weeks, one of the treatment 
regimens was tested. Placebo patches were worn on day 1 of 
each week: on days 2, 3 and 4 one of the active treatment 
sequences was administered and on days 5, 6 and 7 placebo 
patches were again worn (washout period). 
All patients kept a diary to record angina episodes and 
nitroglycerin consumption. Only efficacy was assessed pri- 
marily by serial exercise testing. Tests were performed on 
day 1 of each treatment week and during placebo treatment, 
and again on days 2 and 4 after 1 and 3 days, respectively, of 
active therapy. All tests were performed during the last 2 h 
that the patient wore the active patch: between 2 PM and 4 
PM during the continuous and “6 h off’ regimens and 
between 10 AM and noon during the “10 h off’ sequence. 
Treadmill exercise tests were performed with use of a 
Bruce protocol with the patient fasting or 22 h after a light 
meal. Heart rate and cuff blood pressure were recorded 
before, and at minute intervals during exercise and recovery. 
A 12 lead ECG was recorded before and after exercise; the 
bipolar leads CC,, CM, and ML were monitored continu- 
ously and recorded at minute intervals with use of a com- 
puterized, signal-averaging system (Marquette). Time to 
angina, time to 1 mm ST segment depression, total exercise 
duration and rate-pressure product at each of these points 
were compiled. Exercise was terminated at the level of 
discomfort at which the patient would ordinarily stop. 
Statistical analyses. Paired t tests were used to compare 
treatment and placebo results for angina1 episodes and 
exercise test variables. Total exercise duration was substi- 
tuted for time to angina or time to 1 mm ST depression when 
these end points did not occur during a test. No significant 
treatment effects (including treatment sequence, period and 
potential carryover residual effects) were found by crossover 
analysis. Chi-square and Fisher’s exact tests were used to 
compare discrete clinical variables between responders and 
nonresponders. 
Results 
Exercise testing. The results of the exercise tests for the 
three treatment regimens are listed in Table 2. Exercise 
duration was not increased over levels during placebo ad- 
ministration on either the 1st or the 3rd day of any of the 
three treatment regimens. Exercise-induced ST depression 
occurred in 234 of the 36 patients in each of the three tests 
performed during placebo administration. Active treatment 
did not prevent exercise-induced ST depression, which 
occurred in either 35 or all 36 of the patients on days 1 and 
3 of treatment with each of the three regimens. Furthermore, 
time to 1 mm ST depression was not significantly changed by 
any of the three treatments from values with placebo. 
For each of the nine exercise tests, from 25 to 33 of the 36 
patients experienced angina (Table 3). When angina did not 
occur during a test, exercise duration was substituted for 
angina in the calculation of time to angina. Time to angina 
during active treatment did not differ from placebo values for 
continuous nitroglycerin or for the “6 h off’ regimen but was 
40 2 66 s longer for the “10 h off’ regimen (p = 0.001). 
Eleven patients did not have angina during the day 3 “10 h 
off’ test. 
Heart rate, systolic arterial pressure and rate-pressure 
product at peak exercise were not significantly different 
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Table 2. Exercise Test Variables for the Three Nitroglycerin Regimens in 36 Patients 
Exercise Test Placebo 
Day of 
Treatment* 
Difference: P 
Variable 
Continuous treatment 
Exercise duration 
Time to 1 mm 1 ST 
Time to angina 
6 h off regimen 
Exercise duration 
Time to 1 mm 4 ST 
Time to angina 
IO h off regimen 
Exercise duration 
Time to I mm 4 ST 
Time to angina 
Day* I 3 Day 3 vs. Placebo* Value 
380 3x5 37x -2 + 36 0.73 
229 239 244 IS k 66 0.18 
265 270 272 7 2 72 0.59 
383 387 378 -5 + 36 0.42 
229 254 777 ___ -7 + 54 0.46 
281 2X9 282 1 -’ 96 0.95 
397 402 408 II 2 48 0.16 
281 307 296 16 + 78 0.24 
292 327 332 40 t 66 0.001 
*Mean values (in seconds) for the 36 study patients. 4 ST = ST segment depression 
between placebo and day 3 of treatment for each of the three 
regimens. 
Angina1 episodes. For each of the three treatment weeks, 
the four placebo days were compared with the three days 
with active patch with respect to the number of spontaneous 
episodes of angina (Table 4). Less than one angina1 episode 
per patient per day was noted in each of the periods. 
Compared with the corresponding placebo period, none of 
the treatment regimens significantly decreased the incidence 
of angina1 episodes. 
Treatment responders. Responders to treatment were 
arbitrarily defined as patients whose exercise test end points 
improved by 220% on treatment compared with placebo. 
For total exercise duration, none of the 36 patients were 
responders on continuous therapy, one was a responder on 
the “6 h off’ regimen and 6 were responders on the “IO h 
off’ regimen. For time to I mm ST depression, 12 were 
responders on continuous therapy and 8 on the “6 h off’ and 
14 on the “10 h off’ regimen. For time to angina 8 patients 
were responders on both continuous therapy and the “6 h 
off’ regimen and 13 were responders on the “10 h otf” 
regimen. 
Clinicul and exercise test variables were compared be- 
tween these 13 responders and the other 23 study patients. 
The only clinical variable that correlated with a good drug 
Table 3. Frequency of Angina During Exercise Tests in 
36 Patients 
Patients Experiencing Angina (no.) 
Continuous 
6 h off 
IO h off 
Placebo 
Day 
33 
33 
30 
Day of Treatment 
I 3 
31 31 
30 29 
25 2s 
response was a brief history of angina (p < 0.05). The best 
predictor of a good response to treatment was a poor result 
during the placebo exercise test: 10 of 13 responders, com- 
pared with only 4 of 23 nonresponders (p < O.OOl), had a 
time to angina 5250 s during the placebo test. Response to 
treatment was unrelated to usage of beta-adrenergic blocking 
drugs. 
Adverse effects. Of the 42 patients enrolled in the study 
(including 6 dropouts), 29 (69%) complained of headache on 
the intermittent regimens and 32 (76%) on continuous nitro- 
glycerin patch. Four patients could not complete the study 
because of severe headache; 2.5 required analgesics (aspirin, 
acetaminophen or ibuprofen) during treatment. At some time 
during the trial, 13 (31%) of the 42 subjects reported a 
burning sensation at the patch site and local erythema was 
noted in 6 (14%). 
TK,O patients experienced an acute coronary event (myo- 
cardial infarction in one, and unstable angina in one) during 
washout periods after active treatment. Both had already 
completed without incident a treatment week with a washout 
period. 
Discussion 
In this study a beneficial effect of transdermal nitroglyc- 
erin in patients with stable angina could not be convincingly 
Table 4. Angina1 Episodes/Day During Placebo and Active 
Treatment in 36 Patients 
Treatment 
Angina1 Episodes/Day 
Regimen Placebo Treatment 
Continuous 0.43 + 4.26 0.33 + 3.18 
6 h off 0.42 + 4.14 0.32 i- 3.48 
IOhoff 0.36 + 7.86 0.39 ? 3.48 
p > 0. I for all comparisons. 
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demonstrated by exercise testing. Neither total exercise 
duration nor time to 1 mm ST depression was improved by 
continuous administration of nitroglycerin patch or by inter- 
mittent application with either 6 or 10 h without patch 
therapy. Time to angina was delayed by 40 s (p = 0.001) with 
the “10 h off’ regimen compared with placebo, and 11 of the 
36 patients did not experience angina during exercise; how- 
ever, all but 1 patient still developed ST depression. Spon- 
taneous angina1 attacks, as assessed by patient diary, oc- 
curred infrequently and were not significantly reduced by 
active treatment. 
Previous studies. The intermittent application of nitro- 
glycerin patches has been found to be effective in other 
studies (l&12). In the study of Schaer et al. (lo), exercise 
end points were significantly improved in 11 patients tested 
4 and 8 h after patch application with 10 h/day without patch 
treatment. In contrast to our study, the dose of nitroglycerin 
was titrated to the highest tolerated dose or 20 mg. Cowan et 
al. (11) exercised 11 patients 3.5 h after patch application and 
found the beneficial effects of continuous therapy were 
abolished at 1 week; in contrast, efficacy was preserved with 
intermittent application (12 h/day). Similarly, Luke et al. (12) 
showed in 11 patients that intermittent but not continuous 
therapy remained effective after 1 week; patients underwent 
exercise testing 2 and 4 h after patch application. 
The difference between our results and the data from 
these other studies probably relates to the timing of the 
exercise tests. Tests were performed between 2 and 8 h after 
patch application in these studies, compared with the last 2 
h before patch removal, 12 to 18 h after patch application in 
our trial. Efficacy of nitroglycerin patches can be demon- 
strated relatively easily during the first 8 h after patch 
application (2-12); however, by 24 h most studies (2-5) show 
no benefit. Efficacy is not usually assessed between 8 and 24 
h but is probably waning during this interval. A slight 
superiority for the “10 h off’ regimen might have been 
expected because the exercise test was done 12 to 14 h after 
patch application, as compared with 16 to 18 h with the other 
two treatment regimens. 
Adverse effects. More than half of our study patients 
required analgesics for headache experienced while wearing 
nitroglycerin patches. Nitrate-induced headaches are com- 
mon when therapy is initiated but usually decrease or 
disappear with sustained therapy; loss of headache may 
correspond to loss of therapeutic effect due to the develop- 
ment of tolerance (16). During long-term treatment, head- 
ache may be more common with intermittent administration. 
Patch size in our study was not titrated to individual toler- 
ance. Nevertheless, it is discouraging that very frequently 
side effects occur at a dose level at which prolonged efficacy 
cannot be demonstrated. 
Acute coronary events occurred in two of our patients 
during washout periods after nitroglycerin treatment. The 
cessation of prolonged industrial exposure to nitroglycerin 
has been reported to induce coronary events in isolated 
cases (17); however, nitrate rebound has not been observed 
in studies of angina patients with Holter ECG monitoring 
done at the time of nitroglycerin patch removal (10). That the 
two patients in our study who experienced a coronary event 
were in a washout phase is probably coincidental. 
Limitations of the study. The efficacy of transdermal 
nitroglycerin, even on the 1st day of treatment, was not 
demonstrated in this study. In most (2-12) but not all (13,14) 
previous controlled trials, exercise variables were improved 
when testing was done soon after patch application. The 
absence of improvement in our series can be explained by 
the fact that exercise tests were done 12 to 18 h after patch 
application. Nitroglycerin plasma levels were not measured 
in this study; however, previous pharmacokinetic studies (1) 
with this type of patch have documented stable levels, and 
the high frequency of headache in our patients indirectly 
suggests that drug absorption was adequate. 
A constant dose of a beta-adrenergic blocking drug was 
taken by 26 of the 36 patients during the study. However, 
results were similar in patients with and without concomitant 
therapy. Results in other studies (2-4,1&14) do not appear 
to have been influenced by concomitant drug therapy. 
Clinical implications. The results of this study are difficult 
to reconcile with the widespread clinical acceptability of 
transdermal nitroglycerin patches. For example, in a post- 
marketing surveillance study (18) of 2,461 patients, the 5 
mg/day patch was judged effective in 80.6%, with 70.5% 
experiencing no side effects. Despite large numbers, such 
studies may produce highly misleading results because of the 
use of concomitant medications, a placebo effect and the 
lack of objective end points. A placebo-controlled trial 
produces more reliable results. However, exercise testing 
may not be the optimal method to assess antianginal drug 
efficacy because most episodes of myocardial ischemia oc- 
cur at work loads considerably below the threshold estab- 
lished during exercise testing, and are usually silent (19). The 
pathogenesis of ischemic episodes below exercise threshold 
is not well defined. The clinical efficacy of nitroglycerin may 
be due to its stenosis-dilating (20) or platelet-inhibiting (21) 
activities. These mechanisms may be more important in the 
prevention of ischemic episodes during daily life and be less 
likely to influence exercise test outcome. 
Patients with a poor exercise tolerance were more likely 
to respond favorably to transdermal nitroglycerin in this 
study. However, more than half of the patients required 
analgesics for drug-induced headache and by the time exer- 
cise testing was performed in this study, neither intermittent 
nor continuous treatment improved exercise tolerance over- 
all. Because of these limitations, transdermal nitroglycerin 
does not appear to be optimal therapy for most patients with 
stable angina. 
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